Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. The company is headquartered in San Carlos, California and currently employs 42 full-time employees. The company went IPO on 2021-04-16. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The firm has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.
Quelle est la performance du prix de l'action BMEA ?
Le prix actuel de BMEA est de $1.64, il a augmenté de 2.49% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Biomea Fusion Inc ?
Biomea Fusion Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Biomea Fusion Inc ?
La capitalisation boursière actuelle de Biomea Fusion Inc est de $118.5M
Est-ce que Biomea Fusion Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 8 analystes ont établi des notations d'analystes pour Biomea Fusion Inc, y compris 5 achat fort, 6 achat, 1 maintien, 1 vente et 5 vente forte
